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aTATE-OF-THE-ART PAPER1The Utility of CMR Imaging for Patients With Suspected Myocardial Infarctionan W. Kim, Afshin Farzaneh-Far, Raymond J. Kim
n patients with known or suspected myocardial infarction, cardiovascular magnetic resonance
CMR) provides a comprehensive, multifaceted view of the heart. Kim and colleagues
eview the data, which indicate that delayed enhancement (DE)-CMR is a well-
alidated, robust technique. Because DE-CMR can differentiate between ischemic
nd various nonischemic forms of myocardial injury, it is especially useful when there
s diagnostic uncertainty. Furthermore, CMR provides clinically relevant information,
uch as residual viability, microvascular damage, stunning, and right ventricular infarction.
ecause quantification of infarct size by DE-CMR is highly reproducible, it may provide
useful surrogate end point for clinical trials.TATE-OF-THE-ART PAPER17A Critical Review of Clinical Arteriogenesis Researchiels van Royen, Jan J. Piek, Wolfgang Schaper, William F. Fulton
an Royen and colleagues discuss the potential to exploit the body’s natural processes to
timulate arteriogenesis. This review occurs 50 years after it was conclusively shown that all
ealthy hearts contain an extensive collateral network. Further experimental studies showed
hat the increase in diameter of collateral vessels is not passive dilation; rather, it requires
ctive proliferation of endothelial and smooth muscle cells, suggesting that pharmacological
odulation could stimulate collateral development. To date, clinical trials of arteriogenesis
timulation have had, at best, limited success. The use of intracoronary-derived collateral flow
ndex may increase the sensitivity to detect the effects of pharmacological compounds on
rteriogenesis.(continued on page A-30)
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ENTERVENTIONAL CARDIOLOGY26Optical Coherence Tomography Imaging 5 Years After BMS Implantationasamichi Takano, Masanori Yamamoto, Shigenobu Inami, Daisuke Murakami, Takayoshi Ohba,
oshihiko Seino, Kyoichi Mizuno
akano and colleagues performed optical coherence tomography (OCT) imaging on selected
atients who had a bare-metal stent (BMS) implanted at least 5 years earlier and compared
hose to images taken 6 months after BMS implantation. For stent segments imaged
ithin 6 months, normal neointima proliferated homogeneously and lipid-laden intima was
ot detected. In contrast, after 5 years, lipid-laden intima, intimal disruption, and thrombus
ere frequently found. There was also evidence of intra-intima neovascularization in the late
ut not the early images. This OCT study suggests that neointima within the BMS often
ransforms into lipid-laden tissue during extended follow-up.ditorial Comment: Brigitta C. Brott, p. 33IPIDS AND CORONARY DISEASE35Quantifying Cholesterol-Related Cardiac Riskenoit J. Arsenault, Jamal S. Rana, Erik S. G. Stroes, Jean-Pierre Després, Prediman K. Shah,
ohn J. P. Kastelein, Nicholas J. Wareham, S. Matthijs Boekholdt, Kay-Tee Khaw
rsenault and colleagues tested the hypothesis that at any low-density lipoprotein cholesterol
LDL-C) level, other lipid parameters such as non–high-density lipoprotein cholesterol
HDL-C), triglycerides (TGs), and the total cholesterol (TC)/HDL-C ratio predict the risk
or coronary heart disease (CHD). In the EPIC (European Prospective Investigation Into
ancer and Nutrition)-Norfolk prospective population study, over 20,000 participants without
iabetes or CHD ages 45 to 79 years were followed for 11 years. Among individuals with
DL-C levels 100 mg/dl, those with non–HDL-C 130 mg/dl had a hazard ratio for
uture CHD of 1.84 compared to those with non–HDL-C levels 130 mg/dl. Elevated risk
as also found in those with TG levels 150 mg/dl and those with a TC/HDL-C ratio 5.
n this prospective study, subjects with high non–HDL-C levels, high TG levels, or with an
levated TC/HDL-C ratio were at increased CHD risk, even if their LDL-C level was
nder 100 mg/dl.
ditorial Comment: Jennifer G. Robinson, p. 42(continued on page A-34)
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EEART FAILURE
45igh Rate of Adverse Events During
Pregnancy for Women With Dilated Cardiomyopathy0/12=0% 0/4=0%
1/5=20%
6/14=43%
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No Risk Factor    Risk Factors
Mild LV systolic dysfunction and NYHA I/II
Moderate/severe LV systolic dysfunction
and/or NYHA III/IVasmine Grewal, Samuel C. Siu, Heather J. Ross, Jennifer Mason, Olga H. Balint, Mathew Sermer,
ack M. Colman, Candice K. Silversides
his study sought to determine the rate of adverse events for the fetus and the mother in
omen with a history of a dilated cardiomyopathy (DCM) who become pregnant. A total
f 36 pregnancies in 32 women with DCM were included. Thirty-nine percent of
he pregnancies were complicated by at least 1 maternal cardiac event, most often the
evelopment of pulmonary edema in the third trimester or post-partum. Adverse
bstetric outcomes occurred in 14%, composed of pre-eclampsia and post-partum
emorrhage. Adverse fetal outcomes occurred in 20%, mostly composed of pre-term
elivery (37 weeks) and low birth weight (2,500 g). In pregnant women with DCM,
he risk of adverse cardiac events is considerable, but pre-pregnancy characteristics can
dentify women at the highest risk.EART FAILURE53Mixed Results for NT-proBNP–Guided Treatment for CHFohn G. Lainchbury, Richard W. Troughton, Kim M. Strangman, Christopher M. Frampton, Anna Pilbrow,
imothy G. Yandle, Amjad K. Hamid, M. Gary Nicholls, A. Mark Richards
he concept that periodically measuring N-terminal pro–B-type natriuretic peptide (NT-
roBNP) levels and titrating medications appropriately can improve outcomes for patients
ith chronic heart failure (CHF) is intellectually appealing, but there is limited clinical
vidence to support this. Lainchbury and colleagues conducted a long-term study comparing
he effects of NT-proBNP–guided therapy with intensive clinical management or usual care
fter a hospitalization for CHF, which followed patients for 3 years. One-year mortality was
pproximately 50% lower in both the hormone-guided and intensively-followed groups
ompared with usual care. Three-year mortality was lower in patients age 75 years receiving
ormone-guided treatment. Intensive management of CHF improves 1-year mortality and
ormone-guided treatment may improve long-term mortality in younger patients.
ditorial Comment: Alan Maisel, p. 61(continued on page A-40)
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dEAR IN CARDIOLOGY SERIES65The Year in Hypertensionryan Williams
illiams reviews the literature for clinically-relevant studies regarding the treatment of
ypertension over the last year. Among the recent results that are reviewed include data from
he ONTARGET (Ongoing Telmisartan Alone and in Combination With Ramipril Global
ndpoint Trial) program regarding the efficacy of an angiotensin receptor blocker (ARB) to
educe cardiac events, either alone or in combination with an angiotensin-converting enzyme
ACE) inhibitor. The utility of combination therapy with an ACE inhibitor plus either an
RB or a direct renin inhibitor for preventing the progression of renal dysfunction is also
eviewed. Data from ALLHAT (Antihypertensive and Lipid-Lowering Treatment to Prevent
eart Attack Trial) showing the efficacy of diuretic-based therapy is also summarized, as is
ata on the use of and rationale for single-pill combination therapy.
